Helixmith Participates in US Bio CEO & Investor Conference

[Asia Economy Reporter Chunhee Lee] Helixmith announced on the 17th that it participated in the 'BIO CEO & Investor Conference' held in New York, USA, for four days starting from the 14th.

Now in its 24th year, the BIO CEO & Investor Conference is an event where major global big pharma companies gather to share the latest bio issues. Over 460 multinational pharmaceutical and biotech companies, institutional investors, and researchers from around the world attended, presenting agendas in various fields and conducting one-on-one meetings.

Sunyoung Kim, CEO of Helixmith, introduced Helixmith's gene therapy platform at the conference and focused on the clinical development status of 'Engensis (VM202)'. In addition, through one-on-one partnering meetings with interested companies, discussions were held on technology licensing and investment possibilities.

Engensis is a gene therapy based on plasmid DNA that expresses the HGF protein. It targets the root causes of neuropathy through angiogenesis and nerve regeneration effects beyond simple pain management. Clinical trials are currently underway for various diseases including diabetic peripheral neuropathy (DPN), amyotrophic lateral sclerosis (ALS), and Charcot-Marie-Tooth disease (CMT).

CEO Kim said, “At this event, we informed global companies and investors about the excellence and clinical status of Engensis," adding, "We hope this will lead to meaningful outcomes.”

This content was produced with the assistance of AI translation services.